Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
about
Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer.Sarcopenia and chemotherapy-mediated toxicityInadequacy of Body Weight-Based Recommendations for Individual Protein Intake-Lessons from Body Composition Analysis.A review of body composition and pharmacokinetics in oncology.Muscle mass and association to quality of life in non-small cell lung cancer patients.The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.Clinical Implications of Sarcopenic Obesity in Cancer.Obesity-associated digestive cancers: A review of mechanisms and interventions.Nutrition in peri-operative esophageal cancer management.The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.Impact of Sarcopenic Obesity on Surgical Site Infection after Laparoscopic Total Gastrectomy.Relationship between Handgrip Strength and Muscle Mass in Female Survivors of Breast Cancer: A Mediation Analysis.An analysis of the types of recently published research in the field of cachexia.Impact of body composition on outcome in patients with early breast cancer.Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy.Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer.Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy.
P2860
Q37393133-51CC53E2-6050-4F38-8231-F4AC928851D2Q37572738-B08A8812-E22C-46A9-A490-298B988ADA4EQ37628342-799813EA-523B-45E8-B0AE-37303096786AQ38709340-CA8E4133-13F6-4119-917A-DF2B94A8E12BQ38792305-CDA9F967-11BC-4F66-92DD-A5F11C676BD1Q38842194-78938059-BB6E-49EB-866E-D7A7BEB18EFDQ38931979-3F37C8FF-D0D5-44D0-9776-932BC7110395Q39205170-3CB69466-88E8-44A1-B757-A8FFAE615F6AQ39270534-76DD6E49-CE33-4E6A-ABC2-0343F86A3F3DQ40387345-7B5F4209-C18F-4BF8-92EA-3457BBCEA4BDQ40624769-75E4B4C4-88F7-4BE9-82A4-22122DBFBD3CQ41195096-3F07CE51-E336-4C30-A159-5E578095FBBEQ47568983-B685875E-6E93-4212-928B-3916C45A2D85Q47628315-6D1FCFFA-FE6A-4E67-85BB-725C4985D6ADQ47801764-5FE282B2-DD3A-4AEA-B07A-121D42D4C58AQ50109104-7ABE307C-3F95-4F39-8E35-48F75CCECCA3Q55428382-B94B3872-2F2E-49D6-B965-016BFBD6A3A7
P2860
Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Sarcopenic obesity: A probable ...... n oesophageal cancer patients.
@en
Sarcopenic obesity: A probable ...... n oesophageal cancer patients.
@nl
type
label
Sarcopenic obesity: A probable ...... n oesophageal cancer patients.
@en
Sarcopenic obesity: A probable ...... n oesophageal cancer patients.
@nl
prefLabel
Sarcopenic obesity: A probable ...... n oesophageal cancer patients.
@en
Sarcopenic obesity: A probable ...... n oesophageal cancer patients.
@nl
P2093
P921
P1433
P1476
Sarcopenic obesity: A probable ...... in oesophageal cancer patients
@en
P2093
Asif M Johar
Lena Martin
Poorna Anandavadivelan
P304
P356
10.1016/J.CLNU.2015.05.011
P577
2015-05-27T00:00:00Z